Also known as LY3841136
Eli Lilly’s once-weekly selective amylin receptor agonist — Phase 2 reported up to 20.1% weight loss at 48 weeks; Phase 3 ENLIGHTEN began in 2026.
Research refreshed
Eloralintide is an investigational once-weekly agonist selective for the amylin receptor, developed by Eli Lilly as a non-incretin obesity therapy and as a partner for tirzepatide. Its Phase 2 trial, reported in November 2025, showed up to 20.1% mean weight reduction at 48 weeks versus 0.4% on placebo — the largest effect reported for an amylin agonist alone. The Phase 3 ENLIGHTEN program began in February 2026, and a tirzepatide combination is advancing separately. It is not approved.
Amylin receptors are not single proteins: they are the calcitonin receptor combined with one of three accessory proteins (RAMPs). First-generation long-acting analogs such as cagrilintide activate both the amylin receptors and the bare calcitonin receptor. Eloralintide was designed to favor the amylin receptors — a selectivity Lilly proposes may improve tolerability, though that has not been tested head-to-head.
The Phase 2 dose-ranging trial in adults with obesity or overweight, reported in November 2025, showed mean weight reductions from roughly 9% up to 20.1% at 48 weeks across doses, versus 0.4% on placebo. That moved amylin agonism from "combination partner" to a plausible standalone therapy, with weight loss in the range of injectable semaglutide.
Lilly opened the Phase 3 ENLIGHTEN program in February 2026, including a trial in obesity without diabetes and one in people with persistent obesity despite a weekly incretin. In September 2026 the company reported a Phase 2b study of eloralintide with tirzepatide ("EloraTZP") in which the highest dose produced 23.3% mean weight reduction at 48 weeks in adults with obesity and type 2 diabetes — a population in which weight loss is usually harder — with more gastrointestinal events in the combination arms. Phase 3 for the combination was planned for late 2026.
Selective agonism at amylin receptors (calcitonin receptor paired with RAMPs), with less activity at the calcitonin receptor alone → hindbrain satiety signaling and slowed gastric emptying, independent of the GLP-1 receptor.
Behind every vial of Eloralintide is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Eloralintide, specifically, is brought into being.
On paper, Eloralintide is C201H319N49O65S2 — about 4,526 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Eloralintide is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Eloralintide plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Eloralintide proves itself: identity confirmed by mass spectrometry against its ~4,526 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Eloralintide — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Eloralintide to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Eloralintide, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Eloralintide (LY3841136) is an investigational once-weekly selective amylin receptor agonist from Eli Lilly, studied for obesity alone and in combination with tirzepatide.
The Phase 2 trial reported up to 20.1% mean weight reduction at 48 weeks versus 0.4% on placebo. Phase 3 results are not yet available. Population means, not individual predictions.
No. It acts on amylin receptors, a separate satiety pathway. It is grouped with the GLP-1 agents because it targets the same condition and is being developed as a partner for them.
Both are long-acting amylin-pathway agonists. Cagrilintide activates amylin and calcitonin receptors and is mainly developed with semaglutide as CagriSema; eloralintide is designed to be more selective for amylin receptors and reported larger monotherapy weight loss in Phase 2. No head-to-head trial exists.
No — it is investigational, with Phase 3 trials that began in 2026. This page is a research reference, not medical advice.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.